BRUIN MCL-321: pirtobrutinib vs investigator choice of BTK inhibitor in BTK inhibitor-naive MCL

Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCLПодробнее

Pirtobrutinib for BTK inhibitor-naïve and BTK inhibitor pre-treated R/R MCLПодробнее

Rebooting the BTK Inhibitor Sequence in MCLПодробнее

Updates on the Phase I/II BRUIN study and the role of pirtobrutinib in MCLПодробнее

BRUIN study: updated two-year subgroup analysis of pirtobrutinib for BTKi pre-treated MCLПодробнее

Selecting BTK inhibitors for patients with MCLПодробнее

BRUIN study cohort update: pirtobrutinib for patients with MCLПодробнее

BRUIN MCL-321: Pirtobrutinib in BTKi naïve MCLПодробнее

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCLПодробнее

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

Novel therapies for patients with MCL after failed response to BTK inhibitorsПодробнее

Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trialПодробнее

BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our PatientsПодробнее

Phase I/II BRUIN study: pirtobrutinib in patients intolerant to a covalent BTK inhibitorПодробнее

Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLПодробнее

Efficacy of pirtobrutinib in patients with R/R MCL previously treated with a covalent BTKiПодробнее

Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCLПодробнее

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLLПодробнее

BRUIN MCL-321: Pirtobrutinib en LCM sin tratamiento previo con inhibidores BTKПодробнее